Samsung Bids For US-Based Biogen – Korea Economic Daily

South Korea’s Samsung Group is in negotiations to buy Biogen, a leading US-based drugmaker for neurological diseases such as Alzheimer’s and dementia, Korea Economic Daily reported.

The Nasdaq-listed biotechnology firm approached Samsung to sell its shares, which could be valued at more than 50 trillion won ($42 billion).

Read the full report: Korea Economic Daily.

SEE MORE:

Samsung to Merge Mobile, Consumer Electronics Units

Samsung To Supply Advanced Auto Chips To Volkswagen

Samsung To Pick Taylor, Texas, For $17bn Chip Plant: WSJ

George Russell

George Russell is a freelance writer and editor based in Hong Kong who has lived in Asia since 1996. His work has been published in the Financial Times, The Wall Street Journal, Bloomberg, New York Post, Variety, Forbes and the South China Morning Post.

You Might also Like

Samsung Biologics Buys Out Biogen JV Stake for $2.25bn

Eisai outpaces Biogen in Alzheimer’s drug stock boost